SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
37.89
+0.15 (0.40%)
Apr 17, 2025, 4:00 PM EDT - Market closed
SpringWorks Therapeutics Employees
SpringWorks Therapeutics had 368 employees as of December 31, 2024. The number of employees increased by 63 or 20.66% compared to the previous year.
Employees
368
Change (1Y)
63
Growth (1Y)
20.66%
Revenue / Employee
$520,622
Profits / Employee
-$701,443
Market Cap
2.84B
Employees Chart
SWTX News
- 22 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 5 weeks ago - SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz - Seeking Alpha
- 2 months ago - Top 3 Health Care Stocks You May Want To Dump In February - Benzinga
- 2 months ago - SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 2 months ago - SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over - PRNewsWire
- 2 months ago - Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics - GlobeNewsWire
- 2 months ago - UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 2 months ago - SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire